Grace Therapeutics Inc.

Last updated September 27, 2026

Organization details

Legal name
Grace Therapeutics Inc.
Former names
Acasti Pharma Inc.
Ownership
Public
Status
Active
SIC code
2834 — Pharmaceutical Preparations
Jurisdiction of incorporation
Delaware
Headquarters city
Princeton
Headquarters state / province
New Jersey
Headquarters country
Canada
Fiscal year end
March
Ticker symbol
GRCE
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001444192

Board of directors

Chief executives

Prashant Kohli · Chief Executive Officer
Dates unknown

Director election results

Annual meeting of September 12, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

1 of this board's directors also sit on 1 other board.

Network of Grace Therapeutics Inc.'s board connections Matinas Biopharma Holdings Inc. Matinas Biopharma Hold... Edward Neugeboren Edward Neugeboren Grace Therapeutics Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$301,789
6 purchases by 2 insiders
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Sep 23, 2026 Opaleye Management Inc. 10% owner Open-market purchase +5,318 $2.10 $11,168
Sep 21, 2026 Opaleye Management Inc. 10% owner Open-market purchase +9,771 $2.10 $20,519
Sep 9, 2026 Prashant Kohli Director, Officer (Chief Executive Officer) Open-market purchase +100,000 $2.14 $214,000
Sep 9, 2026 Opaleye Management Inc. 10% owner Open-market purchase +5,836 $2.09 $12,197
Sep 8, 2026 Opaleye Management Inc. 10% owner Open-market purchase +9,393 $2.10 $19,699
Aug 14, 2026 Opaleye Management Inc. 10% owner Open-market purchase +11,608 $2.09 $24,206
Sep 25, 2023 Vimal Kavuru Director, 10% owner Open-market purchase +676,371 $1.85 $1,251,286
Aug 31, 2023 Donald Olds Director Open-market purchase +381 $2.05 $781

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.